Logo Logo
Help
Contact
Switch Language to German
Ruethrich, Maria Madeleine; Giessen-Jung, C.; Borgmann, S.; Classen, A. Y.; Dolff, S.; Gruener, B.; Hanses, F.; Isberner, N.; Koehler, P.; Lanznaster, J.; Merle, U.; Nadalin, S.; Piepel, C.; Schneider, J.; Schons, M.; Strauss, R.; Tometten, L.; Vehreschild, J. J.; Lilienfeld-Toal, M. von; Beutel, G.; Wille, K. (2020): COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. In: Annals of Hematology, Vol. 100, No. 2: pp. 383-393
Full text not available from 'Open Access LMU'.

Abstract

Introduction: Since the early SARS-CoV-2 pandemic, cancer patients have been assumed to be at higher risk for severe COVID-19. Here, we present an analysis of cancer patients from the LEOSS (Lean European Open Survey on SARS-CoV-2 Infected Patients) registry to determine whether cancer patients are at higher risk. Patients and methods We retrospectively analyzed a cohort of 435 cancer patients and 2636 non-cancer patients with confirmed SARS-CoV-2 infection, enrolled between March 16 and August 31, 2020. Data on socio-demographics, comorbidities, cancer-related features and infection course were collected. Age-, sex- and comorbidity-adjusted analysis was performed. Primary endpoint was COVID-19-related mortality. Results In total, 435 cancer patients were included in our analysis. Commonest age category was 76-85 years (36.5%), and 40.5% were female. Solid tumors were seen in 59% and lymphoma and leukemia in 17.5% and 11% of patients. Of these, 54% had an active malignancy, and 22% had recently received anti-cancer treatments. At detection of SARS-CoV-2, the majority (62.5%) presented with mild symptoms. Progression to severe COVID-19 was seen in 55% and ICU admission in 27.5%. COVID-19-related mortality rate was 22.5%. Male sex, advanced age, and active malignancy were associated with higher death rates. Comparing cancer and non-cancer patients, age distribution and comorbidity differed significantly, as did mortality (14% vs 22.5%, p value < 0.001). After adjustments for other risk factors, mortality was comparable. Conclusion Comparing cancer and non-cancer patients, outcome of COVID-19 was comparable after adjusting for age, sex, and comorbidity. However, our results emphasize that cancer patients as a group are at higher risk due to advanced age and pre-existing conditions.